China Over the Counter (OTC) Drugs Market - Databook 2025 to 2034

The China over the counter (OTC) drugs market size accounted for USD 12,485 million in 2024 and is predicted to touch around USD 25,564 million by 2034, growing at a CAGR of 7.42% from 2025 to 2034.

Highlights of the China Over the Counter (OTC) Drugs Market

• By product, the cough & cold products segment underwent notable growth in the market during 2024.
• By product, the analgesic products segment is anticipated to expand rapidly.
• By dosage form, the tablets segment experienced significant expansion in the market.
• By dosage form, the liquids segment is expected to emerge with notable growth during the forecast period.
• By route of administration, the oral segment saw strong growth during the studied period.
• By route of administration, the parenteral segment is expected to see notable performance in growth between 2025–2034.
• By distribution channel, the retail pharmcies segment saw a surge in market performance.
• By distribution channel, the online pharmacies segment is anticipated to demonstrate steady upward momentum during the forecast period.

Industry Valuation and Growth Rate Projection

Over the counter (OTC) drugs can be marketed without a prescription if the Food and Drug Administration (FDA) determines they are effective and safe for use by a consumer without supervision by a licensed healthcare professional. Over the counter (OTC) drugs are also known as non-prescription drugs. OTC drugs help people relieve various symptoms and cure some simple conditions easily and without seeing a doctor.

The China over the counter (OTC) drugs market includes a wide range of applications, including those that can be sold directly without a prescription. OTC medicines treat a variety of illnesses and their symptoms, including acne, constipation, diarrhoea, coughs and colds, pain, and others. In China, OTC drugs include many categories, including skincare drugs, contraceptives, drugs for external use, constipation drugs, tonics, anthelmintics, vitamins, gastric antacids, gastrointestinal prokinetic drugs, pain relievers, cough drugs, and cold drugs.

Market Trends

Suitable regulatory environment: The CDSCO is involved in establishing a strong regulatory structure for over the counter drugs that will support policies. It helps to monitor drug safety through pharmacovigilance (post-marketing surveillance), smooth market access on time, improve product approval & market acceptance, regulatory compliance of drug products with the required standards, and drug safety and efficacy assurance.

Growing senior population: OTC self-medication is a convenient way to manage some health issues, and older persons can be at higher risk of experiencing medicine-related problems. Medicines, the most common medical intervention, are an important part of medical care for senior people. Without medicines, many senior people may function less well or die at an earlier stage.

Restraint

Misuse concerns of drugs:

Major concerns of misuse of drugs include that drug addiction can lead to a range of long-term and short-term mental and physical health problems. Some people who suffer from social anxiety, depression, and stress start using drugs to try to feel less anxious. Stress can play a major role in starting and continuing drug use and also relapse in patients recovering from addiction.

Opportunity

Innovation in product formulation: The development of an innovative drug formulation plays an important role in improving drug efficacy, enhancing patient safety, enhancing drug availability, improving therapeutic outcomes, and promoting adherence. Development in the field, including 3D printing, biologics, personalized medicine, controlled release systems, and nanomedicine & nanotechnology.

Recent Developments in the China Over the Counter (OTC) Drugs Market:

• In September 2024, Lingo over the counter continuous glucose monitoring (CGM) biosensors system will be available without a prescription in the U.S was launched by Abbott.
• In August 2024, the launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1 percent over the counter (OTC), which is compared to the active ingredient in Pataday Twice Daily Relief, was announced by Glenmark Therapeutics Inc., USA (Glenmark).